Registration Number
0215U000353,
0112U001373
, R & D reports
Title
To investigate the mechanisms of influence on hemostasis in vitro and in vivo of clotting factor concentrates and their therapeutic effect in patients with hemophilia with inhibitors
popup.stage_title
Head
Loginsky Volodymyr Eustakhovych, Доктор медичних наук
Registration Date
10-02-2015
Organization
LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE
popup.description2
Object of study were 24 patients with hemophilia A and B, ages 1 to 75 years who were hospitalized in a clinic or outpatient department of SI " Institute of Blood Pathology and Transfusion Medicine, Academy of Medical Sciences of Ukraine" Aim. To develop methods for predicting the severity of hemorrhagic manifestations and determine efficacy concentrates of factor VIII, recombinant activated factor VII, coagulation factors II, VII, IX, X , and their combination in hemophilia A patients with inhibitors based on coagulation test in vitro and in vivo. Methods. Clinical and laboratory studies included clinical examination , coagulation tests, hematology, biochemical research. It used Micros 60 hematology analyzer T number 81473 , biochemical analyzer Point +180, SR 1907.1674, coagulometer Helena- C4 C4- number 2489. Results. pharmacokinetic study is necessary for the individual selection of the optimal dose, frequency of administration for the purpose of rational use of drugs and reduce the cost of treatment. Investigation of the recovery period introduced factor VIII (IX) can be recommended as a screening test for the diagnosis of inhibitor hemophilia A and B. The recovery index (Ir) can be recommended for individual dose calculation administration of the drug factor VIII and IX. Revealed that the pharmacokinetic parameters depend to a greater extent on the individual patient, and to a lesser extent of the type of preparation of coagulation factor VIII (IX). In patients with haemophilia with or without inhibitors ex vivo / in vitro studied the effect on clotting by-passing agents: non activated prothrombin complex (PCC), activated prothrombin complex (Anti-Inhibitor Coagulant Complex - aPCC) and recombinant activated factor VII (rFVIIa). Modeled ex vivo / in vitro experiment was carried out on the basis of a test of the activated partial thromboplastin time (APTT). In patients with haemophilia with inhibitors index shortening APTT when added to plasma ex vivo / in vitro preparations APCC and rFVIIa associated strong correlative connection with the clinical response to the treatment. Dynamics inhibitor in patients with hemophilia during therapy was individual and did not depend on the initial titer inhibitor type of immune response, the dose and type of treatment.
Product Description
popup.authors
Дзісь Р.П.
Красівська В.В.
Стасишин О.В.
Тушницький О.М.
popup.nrat_date
2020-04-02
